Bioforce Nanosciences Holdings, Inc. (BFNH) — SEC Filings
Bioforce Nanosciences Holdings, Inc. (BFNH) — 10 SEC filings. Latest: 10-K (Apr 15, 2026). Includes 6 10-Q, 3 10-K, 1 8-K.
View Bioforce Nanosciences Holdings, Inc. on SEC EDGAR
Overview
Bioforce Nanosciences Holdings, Inc. (BFNH) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 19, 2025: BIOFORCE NANOSCIENCES HOLDINGS, INC. (BFNH) reported no revenue for the three and nine months ended September 30, 2025, consistent with the prior year. The company incurred a net loss of $115,915 for the three months ended September 30, 2025, a slight improvement from a net loss of $122,024 in the s
Sentiment Summary
Across 10 filings, the sentiment breakdown is: 2 bearish, 8 neutral. The dominant filing sentiment for Bioforce Nanosciences Holdings, Inc. is neutral.
Filing Type Overview
Bioforce Nanosciences Holdings, Inc. (BFNH) has filed 3 10-K, 6 10-Q, 1 8-K with the SEC between Apr 2024 to Apr 2026.
Filings by Year
Recent SEC Filings (10)
| Date | Form | Description | Risk |
|---|---|---|---|
| Apr 15, 2026 | 10-K | 10-K Filing | |
| Nov 19, 2025 | 10-Q | BIOFORCE Nanosciences Reports Zero Revenue, Widening Losses Amidst Going Concern Doubt | high |
| Aug 11, 2025 | 10-Q | BIOFORCE Nanosciences Reports Zero Revenue, Continues Equity Issuances | high |
| May 13, 2025 | 10-Q | BioForce Nanosciences Files Q1 2025 10-Q | low |
| Apr 8, 2025 | 10-K | BioForce Nanosciences Files 2024 10-K | low |
| Nov 8, 2024 | 10-Q | BioForce Nanosciences Files Q3 2024 10-Q | medium |
| Aug 7, 2024 | 10-Q | BioForce Nanosciences Files Q2 2024 10-Q | medium |
| May 7, 2024 | 8-K | Bioforce Nanosciences Changes Auditors | medium |
| May 3, 2024 | 10-Q | BioForce Nanosciences Holdings, Inc. Files Quarterly Report for Period Ended March 31, 2024 | low |
| Apr 1, 2024 | 10-K | BioForce Nanosciences Holdings, Inc. Files 2023 Annual Report | low |
Risk Profile
Risk Assessment: Of BFNH's 9 recent filings, 2 were flagged as high-risk, 3 as medium-risk, and 4 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $0 |
| Net Income | $(1,173,346) |
| EPS | $(0.04) |
| Debt-to-Equity | N/A |
| Cash Position | $784 |
| Operating Margin | N/A |
| Total Assets | $784 |
| Total Debt | $500,722 |
Key Executives
- Mr. Richard Kaiser
- Mr. Merle Ferguson
- Mr. Merle
- Mr. Ferguson
- Richard Kaiser
- Richard W. Jones, Esq.
Industry Context
BioForce Nanosciences Holdings, Inc. operates in the nutritional supplements market, a sector characterized by a wide array of products and brands. The company focuses on private labeling vitamins, minerals, powders, and beverages for active individuals. Key distribution channels include retailers, sporting goods stores, supermarkets, and online platforms.
Top Tags
financials (4) · 10-Q (3) · reporting (3) · Zero Revenue (2) · Net Loss (2) · Penny Stock (2) · 10-K (2) · BioForce Nanosciences (2) · Going Concern (1) · Related Party Transactions (1)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Sales | $0 | for the three and nine months ended September 30, 2025 and 2024, indicating no revenue generation |
| Net Loss | $(1,173,346) | for the nine months ended September 30, 2025, significantly higher than $(367,277) in 2024 |
| Loss on Liability Settlement | $801,193 | incurred during the nine months ended September 30, 2025, contributing to the increased net loss |
| Cash | $784 | at September 30, 2025, a critically low balance |
| Total Current Liabilities | $500,722 | at September 30, 2025, down from $2,302,454 at December 31, 2024 |
| Common Shares Outstanding | 33,521,755 | as of November 18, 2025, including 4,250,000 shares issued to Mr. Ferguson |
| Net Loss Per Common Share | $0.04 | for the nine months ended September 30, 2025 |
| Related Party Deposit | $10,000 | received on November 10, 2025, to cover professional and operational fees |
| Revenue | $0 | for the three and six months ended June 30, 2025, unchanged from prior year |
| Net Loss (Q2) | $10,000 | for the three months ended June 30, 2025, identical to Q2 2024 |
| Net Loss (YTD) | $20,000 | for the six months ended June 30, 2025, identical to YTD 2024 |
| Common Shares Issued | 30,000,000 | for services to Mr. Merle, Mr. Ferguson, and Richard Kaiser during H1 2025 |
| Series A Preferred Stock Issued | 10,000,000 | to Mr. Merle for $10,000 during H1 2025 |
| Accumulated Deficit | $1,000,000 | as of June 30, 2025, unchanged from December 31, 2024 |
| Reporting Period End | 2025-03-31 | The end date for the financial data presented in this 10-Q filing. |
Frequently Asked Questions
What are the latest SEC filings for Bioforce Nanosciences Holdings, Inc. (BFNH)?
Bioforce Nanosciences Holdings, Inc. has 10 recent SEC filings from Apr 2024 to Apr 2026, including 6 10-Q, 3 10-K, 1 8-K. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of BFNH filings?
Across 10 filings, the sentiment breakdown is: 2 bearish, 8 neutral. The dominant sentiment is neutral.
Where can I find Bioforce Nanosciences Holdings, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Bioforce Nanosciences Holdings, Inc. (BFNH) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Bioforce Nanosciences Holdings, Inc.?
Key financial highlights from Bioforce Nanosciences Holdings, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for BFNH?
The investment thesis for BFNH includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Bioforce Nanosciences Holdings, Inc.?
Key executives identified across Bioforce Nanosciences Holdings, Inc.'s filings include Mr. Richard Kaiser, Mr. Merle Ferguson, Mr. Merle, Mr. Ferguson, Richard Kaiser and 1 others.
What are the main risk factors for Bioforce Nanosciences Holdings, Inc. stock?
Of BFNH's 9 assessed filings, 2 were flagged high-risk, 3 medium-risk, and 4 low-risk.
What are recent predictions and forward guidance from Bioforce Nanosciences Holdings, Inc.?
Forward guidance and predictions for Bioforce Nanosciences Holdings, Inc. are extracted from SEC filings as they are enriched.